The estimated Net Worth of William F Doyle is at least $66.7 Million dollars as of 21 May 2024. Mr. Doyle owns over 15,000 units of NovoCure Ltd stock worth over $1,315,166 and over the last 9 years he sold NVCR stock worth over $57,127,040. In addition, he makes $8,286,100 as Executive Chairman of the Board at NovoCure Ltd.
William has made over 36 trades of the NovoCure Ltd stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 15,000 units of NVCR stock worth $254,700 on 21 May 2024.
The largest trade he's ever made was selling 150,000 units of NovoCure Ltd stock on 20 November 2019 worth over $13,554,000. On average, William trades about 20,035 units every 41 days since 2016. As of 21 May 2024 he still owns at least 76,330 units of NovoCure Ltd stock.
You can see the complete history of Mr. Doyle stock trades at the bottom of the page.
William F. Doyle serves as Executive Chairman of the Board of the Company. Mr. Doyle has served as a director of Optinose, Inc., a commercial-stage specialty pharmaceuticals company, since 2004 and Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, since 2017. Mr. Doyle has also been the managing director of WFD Ventures LLC, a private venture capital firm he co-founded, since 2002 and was formerly a member of the investment team at Pershing Square Capital Management L.P., a private investment firm. Prior to 2002, Mr. Doyle was a member of Johnson & Johnson’s Medical Devices and Diagnostics Group Operating Committee and was vice president, Licensing and Acquisitions. While at Johnson & Johnson, Mr. Doyle was also chairman of the Medical Devices Research and Development Council, Worldwide president of Biosense-Webster, Inc. and a member of the board of directors of Cordis Corporation and Johnson & Johnson Development Corporation, Johnson & Johnson’s venture capital subsidiary. Mr. Doyle holds an S.B. in materials science and engineering from the Massachusetts Institute of Technology and an M.B.A. from Harvard Business School. Mr. Doyle serves on Harvard Business School’s Board of Dean’s Advisors and MIT’s Institute of Medical Engineering & Science Visiting Committee. Mr. Doyle holds an S.B. in materials science and engineering from the Massachusetts Institute of Technology and an M.B.A. from Harvard Business School.
As the Executive Chairman of the Board of NovoCure Ltd, the total compensation of William Doyle at NovoCure Ltd is $8,286,100. There are no executives at NovoCure Ltd getting paid more.
William Doyle is 57, he's been the Executive Chairman of the Board of NovoCure Ltd since 2016. There are 15 older and 9 younger executives at NovoCure Ltd. The oldest executive at NovoCure Ltd is Prof. Yoram Palti, 83, who is the Founder & CTO.
William's mailing address filed with the SEC is C/O ELANCO ANIMAL HEALTH INCORPORATED, 2500 INNOVATION WAY, GREENFIELD, IN, 46140.
Over the last 9 years, insiders at NovoCure Ltd have traded over $237,132,855 worth of NovoCure Ltd stock and bought 164,174 units worth $2,198,429 . The most active insiders traders include Asaf Danziger, William Fwfd Ventures Fund ..., and Michael J. Ambrogi. On average, NovoCure Ltd executives and independent directors trade stock every 7 days with the average trade being worth of $853,350. The most recent stock trade was executed by Ashley Cordova on 2 August 2024, trading 688 units of NVCR stock currently worth $13,856.
we are a commercial-stage oncology company developing a novel, proprietary therapy called tumor treating fields, or ttfields, for the treatment of solid tumor cancers. we count on the contributions of our talented team members who are committed to improving the lives of cancer patients. here at novocure, cancer patients and their families are – and have always been – at the core of our mission. we expect our colleagues to excel, and in return, we invest in their professional growth and personal well-being. we seek high performers who thrive in fast-paced environments and are inspired by making a difference in cancer care. we offer employment opportunities in the u.s., europe and asia.
NovoCure Ltd executives and other stock owners filed with the SEC include: